GlaxoSmithKline's Tyverb Gets Positive EMEA Opinion

GlaxoSmithKline said it has received a positive opinion and conditional approval from the European Medicines Agency (EMEA) for its Tyverb cancer medicine after the product passed a Phase III trial.
Hemscott